^
Association details:
| Biomarker: | TNFRSF8 positive |
|---|---|
| Cancer: | Non-Hodgkin’s Lymphoma |
| Drug Class: | T-lymphocyte cell therapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
164 Phase 1 Clinical Trial of Memory-Enriched Academic HSP-CAR30 for the Treatment of Relapsed/Refractory Hodgkin Lymphoma and CD30+ T-Cell Lymphoma: Clinical and Biological Studies
Published date:
11/03/2022
Excerpt:
We conducted a phase 1 dose-escalation study in 11 patients with R/R HL or CD30+ T-NHL….Our Phase 1 study provides evidence for feasibility and safety of HSP-CAR30. Additionally, HSP-CAR30 has shown promising efficacy in heavily treated cHL patient population, and this is being explored in the phase 2.
DOI:
https://doi.org/10.1182/blood-2022-167504
Trial ID:
